Welcome to our dedicated page for Currenc Group news (Ticker: CURR), a resource for investors and traders seeking the latest updates and insights on Currenc Group stock.
Currenc Group Inc (CURR) delivers cutting-edge fintech solutions through its interoperable digital banking platform. This news hub provides investors and financial professionals with timely updates on strategic developments shaping the future of real-time payments and secure financial messaging.
Access curated press releases and analysis covering earnings reports, partnership announcements, product innovations, and regulatory milestones. Our repository helps stakeholders track the company's progress in enabling frictionless transactions for global institutions and merchants.
Key coverage areas: quarterly financial results, e-wallet feature updates, cross-border payment network expansions, and cybersecurity enhancements. Bookmark this page to monitor how CURR continues advancing integrated financial infrastructure through its instant fund transfer capabilities and communication tools.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced the upcoming issuance of U.S. Patent No. 11,179,331 for its product CUREfilm Blue™, an oral soluble film containing sildenafil citrate, aimed at treating erectile dysfunction (ED). This innovative drug delivery method utilizes CURE's proprietary CUREfilm™ technology, enhancing patient experience with discreet and convenient administration. The erectile dysfunction drug market is projected to reach approximately USD$6.6 billion by 2025, with significant growth expected for sildenafil.
CURE Pharmaceutical Holding Corp. (OTC: CURR) reported a remarkable 700% revenue increase to $2.1 million for Q2 2021, with gross profit rising 676% to $1.31 million. The net loss decreased significantly to $3.27 million from a loss of $13.47 million year-over-year. Key developments include CVS's upcoming launch of the Seratopical Revolution skincare line, ISO 9001 certification for its facility, successful initial clinical trials of CUREfilm Blue™, and a partnership with Biopharmaceutical Research Company to create cannabis-based medical products for Veterans.
CURE Pharmaceutical (OTC: CURR) announced that its skincare line, Seratopical Revolution, will be available at CVS starting Fall 2021. This partnership positions CURR for expansive market reach, targeting diverse customer needs with its innovative P3P complex, which enhances product efficacy without drying effects. CEO Nancy Duitch highlighted the brand's competitive edge through effective delivery systems and attractive packaging, alongside actress Nicole Kidman as a global ambassador. This development signifies an important milestone for CURR's growth strategy in the beauty industry.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced that Chief Business Officer Jonathan Berlent will present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17 at 7:00 a.m. EST. Berlent expressed pride in developing the company's psychedelic-based clinical pipeline, emphasizing the therapeutic potential of psychedelics for mental health disorders. The presentation will be accessible online for 90 days post-event. CURE is a leader in innovative drug delivery systems, operating from a state-of-the-art facility.
CURE Pharmaceutical Holding Corp. (OTC: CURR) has launched Seratopical Revolution, a new line of anti-aging beauty products developed in collaboration with global brand ambassador Nicole Kidman. The product line features 11 plant-based items designed to hydrate and rejuvenate skin, utilizing a proprietary delivery system that enhances absorption. Products are made in the U.S. and are affordably priced. The line includes items such as Loving Hands Essential Oil and Indulgence Brown Sugar Scrub, aiming to merge nature and science for effective skincare.
CURE Pharmaceutical Holding Corp. (OTC: CURR) will hold a webcast on May 27, 2021, at 5 p.m. EDT for its investors. CEO Rob Davidson and Nancy Duitch, CEO of The Sera Labs, will discuss the company's future positioning and current achievements. Shareholders are encouraged to submit questions before the event. The company operates a 25,000 sq. ft. FDA-registered manufacturing facility and is known for its CUREform™ drug delivery platform, which enhances drug efficacy and safety.
CURE Pharmaceutical (OTC: CURR) reported a significant Q1 2021 performance, with total revenue soaring over 400% year-on-year to $1.5 million. The company received FDA approval for its Investigational New Drug application for CUREfilm Blue™, targeting erectile dysfunction. Additionally, CURE is advancing clinical development of delivery vehicles for psychedelic compounds. A new line of Nutri-Strips™ vitamins was launched via its Sera Labs subsidiary. CURE also secured a $2.3 million payment from a resolved contract dispute in April 2021.
Sera Labs, part of CURE Pharmaceutical (OTC: CURR), highlighted their participation in Collision 2021, a major tech conference, where CEO Nancy Duitch and actress Nicole Kidman discussed their collaboration and product innovation. The discussion emphasized their upcoming Q2 plant-based product launch and the importance of their proprietary PꝫP complex delivery systems in enhancing product efficacy. Duitch noted that the event generated substantial business momentum for Sera Labs, positioning them to set new standards in wellness and beauty.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced successful results from its Pharmacokinetics (PK)/bioequivalence studies, paving the way for further clinical development aimed at FDA approval. Utilizing its patented CUREfilm technology, the company is developing CUREfilm Blue™, an oral film for sildenafil citrate, enhancing patient experience by eliminating the need to swallow pills. CURE is excited to advance its partnering initiatives for commercialization following these promising results.
FAQ
What is the current stock price of Currenc Group (CURR)?
What is the market cap of Currenc Group (CURR)?
